STAT3 and non-small cell lung carcinoma: Numerous studies have also demonstrated the essential role of STAT3 in the development of drug resistance toward epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): high levels of STAT3 have been recently reported to predict worse progression-free survival.in patients affected by Non-Small Cell Lung Cancer (NSCLC) harboring EGFR activating mutations treated with this class of drugs [36, 37].